Azitra Inc (AZTR)
Azitra Inc. is an early-stage clinical biopharmaceutical company focused on precision dermatology. The company develops engineered proteins and topical live biotherapeutic products aimed at treating skin diseases in the United States. Its pipeline includes ATR-04, a genetically modified S. epidermidis strain being studied in a Phase 1/2 trial for the papulopustular rash associated with epidermal growth factor receptor inhibitor therapy in cancer patients; ATR-12, a genetically modified S. epidermidis strain in a Phase 1b/2a trial for Netherton syndrome; and ATR-01, a genetically modified S. epidermidis strain expressing engineered recombinant human filaggrin, which is in the IND-enabling stage for ichthyosis vulgaris. Azitra also has a joint development agreement with Bayer related to the identification and characterization of S. epidermidis strains for topical formulations. The company was incorporated in 2014 and is headquartered in Branford, Connecticut.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-AZTR
|
$0.22
|
24.3% Upside
|
Undervalued
|
$0.78
|
345.4% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
1.4x
|
10.545 M
|
4.227 M
|
3.7%
|
84.6%
|
-12.2
|
91.0%
|
